SQ109, a new drug lead for chagas disease

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1950-1961

  Veiga Santos, Phercyles ^a   Li, Kai ^b   Lameira, Lilianne ^a   De Carvalho, Tecia Maria Ulisses ^a   Huang, Guozhong ^c   Galizzi, Melina ^c   Shang, Na ^d   Li, Qian ^d   Gonzalez Pacanowska, Dolores ^e   Hernandez Rodriguez, Vanessa ^f   Benaim, Gustavo ^f   Guo, Rey Ting ^d   Urbina, Julio A ^g   Docampo, Roberto ^c   De Souza, Wanderley ^a,h   Oldfield, Eric ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^e INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^f Fundacion Instituto de Estudios Avanzados IDEA   (Venezuela)

^g INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^h INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL CYANIDE 4 (TRIFLUOROMETHOXY)PHENYLHYDRAZONE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; POSACONAZOLE; SQUALENE SYNTHASE; STEROL; SUCCINIC ACID; ADAMANTANE; ANTITRYPANOSOMAL AGENT; ETHYLENEDIAMINE DERIVATIVE; N-GERANYL-N'-(2-ADAMANTYL)ETHANE-1,2-DIAMINE; SQUALENE; TRIAZOLE DERIVATIVE;

ALKALINIZATION; AMASTIGOTE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING SITE; CELL KILLING; CELL STRUCTURE; CHAGAS DISEASE; CYTOLYSIS; DRUG POTENTIATION; DRUG STRUCTURE; EC50; EPIMASTIGOTE; HUMAN; IC50; LIFE CYCLE; MICROSCOPY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STEROL SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; HEMOLYSIS; IN VITRO STUDY; LLC PK1 CELL LINE; PIG;

ADAMANTANE; ANIMALS; CHAGAS DISEASE; ETHYLENEDIAMINES; HEMOLYSIS; HUMANS; IN VITRO TECHNIQUES; LLC-PK1 CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; SQUALENE; STEROLS; SWINE; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84928901526     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03972-14     Document Type: Article

References (53)

1. World Health Organization. 2014. Chagas disease (American trypanosomiasis). World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs340/en/.
2. Centers for Disease Control and Prevention. 2013. Parasites-American trypanosomiasis (also known as Chagas disease). Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/parasites/chagas/epi.html.
3. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. 2013. Global economic burden of Chagas disease: a computational simulation model. Lancet Infect Dis 13:342-348. http://dx.doi.org/10.1016/S1473-3099(13)70002-1.
4. Ellis C. 2003. Antifungals: doing the two step. Nat Rev Drug Discov 2:605. http://dx.doi.org/10.1038/nrd1167.
5. Courchesne WE. 2002. Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther 300:195-199. http://dx.doi.org/10.1124/jpet.300.1.195.
6. Gupta SS, Ton VK, Beaudry V, Rulli S, Cunningham K, Rao R. 2003. Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 278:28831-28839. http://dx.doi.org/10.1074/jbc.M303300200.
7. Benaim G, Sanders JM, Garcia-Marchan Y, Colina C, Lira R, Caldera AR, Payares G, Sanoja C, Burgos JM, Leon-Rossell A, Concepcion JL, Schijman AG, Levin M, Oldfield E, Urbina JA. 2006. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 49:892-899. http://dx.doi.org/10.1021/jm050691f.
8. Serrano-Martín X, Garcia-Marchan Y, Fernandez A, Rodriguez N, Rojas H, Visbal G, Benaim G. 2009. Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana. Antimicrob Agents Chemother 53:1403-1410. http://dx.doi.org/10.1128/AAC.01215-08.
9. de Macedo-Silva ST, de Oliveira Silva TL, Urbina JA, de Souza W, Rodrigues JC. 2011. Antiproliferative, ultrastructural, and physiological effects of amiodarone on promastigote and amastigote forms of Leishmania amazonensis. Mol Biol Int 2011:876021. http://dx.doi.org/10.4061/2011/876021.
10. Paniz-Mondolfi AE, Perez-Alvarez AM, Lanza G, Marquez E, Concepcion JL. 2009. Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease. Chemotherapy 55: 228-233. http://dx.doi.org/10.1159/000219436.
11. Paniz-Mondolfi AE, Perez-Alvarez AM, Reyes-Jaimes O, Socorro G, Zerpa O, Slova D, Concepcion JL. 2008. Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: the role of amiodarone as an antitrypanosomatidae drug. Ther Clin Risk Manag 4:659-663. http://dx.doi.org/10.2147/TCRM.S2801.
12. Benaim G, Paniz Mondolfi AE. 2012. The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol 9:605-609. http://dx.doi.org/10.1038/nrcardio.2012.108.
13. Benaim G, Hernandez-Rodriguez V, Mujica-Gonzalez S, Plaza-Rojas L, Silva ML, Parra-Gimenez N, Garcia-Marchan Y, Paniz-Mondolfi A, Uzcanga G. 2012. In vitro anti-Trypanosoma cruzi activity of dronedarone, a novel amiodarone derivative with an improved safety profile. Antimicrob Agents Chemother 56:3720-3725. http://dx.doi.org/10.1128/AAC.00207-12.
14. Spaniol M, Bracher R, Ha HR, Follath F, Krahenbuhl S. 2001. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J Hepatol 35:628-636. http://dx.doi.org/10.1016/S0168-8278(01) 00189-1.
15. Peña A, Calahorra M, Michel B, Ramirez J, Sanchez NS. 2009. Effects of amiodarone on K+, internal pH and Ca2+ homeostasis in Saccharomyces cerevisiae. FEMS Yeast Res 9:832-848. http://dx.doi.org/10.1111/j.1567-1364.2009.00538.x.
16. Felser A, Blum K, Lindinger PW, Bouitbir J, Krahenbuhl S. 2013. Mechanisms of hepatocellular toxicity associated with dronedarone-a comparison to amiodarone. Toxicol Sci 131:480-490. http://dx.doi.org/10.1093/toxsci/kfs298.
17. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. 2005. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56:968-974. http://dx.doi.org/10.1093/jac/dki319.
18. Sacksteder KA, Protopopova M, Barry CE, III, Andries K, Nacy CA. 2012. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 7:823-837. http://dx.doi.org/10.2217/fmb.12.56.
19. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388-. http://dx.doi.org/10.1038/nrd4001.
20. Stehr M, Elamin AA, Singh M. 2014. Filling the pipeline-new drugs for an old disease. Curr Top Med Chem 14:110-129. http://dx.doi.org/10.2174/1568026613666131113152908.
21. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, III, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797-1809. http://dx.doi.org/10.1128/AAC.05708-11.
22. Makobongo MO, Einck L, Peek RM, Jr, Merrell DS. 2013. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS One 8:e68917. http://dx.doi.org/10.1371/journal.pone .0068917.
23. Anonymous. 2008. Sq109. Tuberculosis (Edinb) 88:159-161. http://dx.doi.org/10.1016/S1472-9792(08)70026-X.
24. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu YL, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo RT, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126-3139. http://dx.doi.org/10.1021/jm500131s.
25. Lin FY, Liu YL, Li K, Cao R, Zhu W, Axelson J, Pang R, Oldfield E. 2012. Head-to-head prenyl tranferases: anti-infective drug targets. J Med Chem 55:4367-4372. http://dx.doi.org/10.1021/jm300208p.
26. Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E. 2008. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319:1391-1394. http://dx.doi.org/10.1126/science.1153018.
27. Lin FY, Liu CI, Liu YL, Zhang Y, Wang K, Jeng WY, Ko TP, Cao R, Wang AH, Oldfield E. 2010. Mechanism of action and inhibition of dehydrosqualene synthase. Proc Natl Acad Sci U S A 107:21337-21342. http://dx.doi.org/10.1073/pnas.1010907107.
28. Pandit J, Danley DE, Schulte GK, Mazzalupo S, Pauly TA, Hayward CM, Hamanaka ES, Thompson JF, Harwood HJ, Jr. 2000. Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. J Biol Chem 275:30610-30617. http://dx.doi.org/10.1074/jbc.M004132200.
29. Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, Guhl F, Lages-Silva E, Macedo AM, Machado CR, Miles MA, Romanha AJ, Sturm NR, Tibayrenc M, Schijman AG, Second Satellite Meeting. 2009. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz 104:1051-1054. http://dx.doi.org/10.1590/S0074-02762009000700021.
30. Camargo EP. 1964. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev Inst Med Trop Sao Paulo 6:93-100.
31. Henriques C, Moreira TLB, Maia-Brigagao C, Henriques-Pons A, Carvalho TMU, de Souza W. 2011. Tetrazolium salt based methods for high-throughput evaluation of anti-parasite chemotherapy. Anal Methods 3:2148-2155. http://dx.doi.org/10.1039/c1ay05219e.
32. Veiga-Santos P, Barrias ES, Santos JF, de Barros Moreira TL, de Carvalho TM, Urbina JA, de Souza W. 2012. Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents 40:61-71. http://dx.doi.org/10.1016/j.ijantimicag.2012.03.009.
33. Shang N, Li Q, Ko TP, Chan HC, Li J, Zheng Y, Huang CH, Ren F, Chen CC, Zhu Z, Galizzi M, Li ZH, Rodrigues-Poveda CA, Gonzalez-Pacanowska D, Veiga-Santos P, de Carvalho TM, de Souza W, Urbina JA, Wang AH, Docampo R, Li K, Liu YL, Oldfield E, Guo RT. 2014. Squalene synthase as a target for Chagas disease therapeutics. PLoS Pathog 10:e1004114. http://dx.doi.org/10.1371/journal.ppat.1004114.
34. Hallander HO, Dornbusch K, Gezelius L, Jacobson K, Karlsson I. 1982. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother 22:743-752. http://dx.doi.org/10.1128/AAC.22.5.743.
35. Veiga-Santos P, Pelizzaro-Rocha KJ, Santos AO, Ueda-Nakamura T, Dias Filho BP, Silva SO, Sudatti DB, Bianco EM, Pereira RC, Nakamura CV. 2010. In vitro anti-trypanosomal activity of elatol isolated from red seaweed Laurencia dendroidea. Parasitology 137:1661-1670. http://dx.doi.org/10.1017/S003118201000034X.
36. Vercesi AE, Bernardes CF, Hoffmann ME, Gadelha FR, Docampo R. 1991. Digitonin permeabilization does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of Trypanosoma cruzi in situ. J Biol Chem 266:14431-14434.
37. Huang G, Vercesi AE, Docampo R. 2013. Essential regulation of cell bioenergetics in Trypanosoma brucei by the mitochondrial calcium uniporter. Nat Commun 4:2865. http://dx.doi.org/10.1038/ncomms3865.
38. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta CrystallogrDBiol Crystallogr 54(Pt 5):905-921. http://dx.doi.org/10.1107/S0907444998003254.
39. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501. http://dx.doi.org/10.1107/S0907444910007493.
40. Schrödinger. 2014. PyMOL, a molecular visualization system on an open source foundation, maintained and distributed by Schrödinger. Schrödinger, New York, NY.
41. Sealey-Cardona M, Cammerer S, Jones S, Ruiz-Perez LM, Brun R, Gilbert IH, Urbina JA, Gonzalez-Pacanowska D. 2007. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother 51:2123-2129. http://dx.doi.org/10.1128/AAC.01454-06.
42. Larralde G, Vivas J, Urbina JA. 1988. Concentration and time dependence of the effects of ketoconazole on growth and sterol synthesis by Trypanosoma (Schizotrypanum) cruzi epimastigotes. Acta Cient Venez 39: 140-146.
43. Urbina JA, Lazardi K, Aguirre T, Piras MM, Piras R. 1988. Antiproliferative synergism of the allylamine SF86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 32:1237-1242. http://dx.doi.org/10.1128/AAC.32.8.1237.
44. Urbina JA, Vivas J, Visbal G, Contreras LM. 1995. Modification of the sterol composition of Trypanosoma (Schizotrypanum) cruzi apimastigotes by delta 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol Biochem Parasitol 73:199-210. http://dx.doi.org/10.1016/0166-6851(95)00117-J.
45. Rodrigues JCF, Attias M, Rodriguez C, Urbina JA, de Souza W. 2002. Ultrastructural and biochemical alterations induced by 22,26-azasterol, a Δ24(25)-sterol methyltransferase inhibitor, on promastigote and amastigote forms of Leishmania amazonensis. Antimicrob Agents Chemother 46:487-499. http://dx.doi.org/10.1128/AAC.46.2.487-499.2002.
46. Liendo A, Visbal G, Piras MM, Piras R, Urbina JA. 1999. Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. Mol Biochem Parasit 104:81-91. http://dx.doi.org/10.1016/S0166-6851(99) 00129-2.
47. Urbina JA, Payares G, Contreras LM, Liendo A, Sanoja C, Molina J, Piras M, Piras R, Perez N, Wincker P, Loebenberg D. 1998. Antiproliferative effects and mechanism of action of SCH56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 42:1771-1777.
48. Urbina JA, Concepcion JL, Rangel S, Visbal G, Lira R. 2002. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 125:35-45. http://dx.doi.org/10.1016/S0166-6851(02)00206-2.
49. Urbina JA, Concepcion JL, Caldera A, Payares G, Sanoja C, Otomo T, Hiyoshi H. 2004. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 48:2379-2387. http://dx.doi.org/10.1128/AAC.48.7.2379-2387.2004.
50. Fernandes Rodrigues JC, Concepcion JL, Rodrigues C, Caldera A, Urbina JA, de Souza W. 2008. In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother 52:4098-4114. http://dx.doi.org/10.1128/AAC.01616-07.
51. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. 2005. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 144:80-87. http://dx.doi.org/10.1038/sj.bjp.0705984.
52. Urbina JA. 2010. New insights in Chagas disease treatment. Drugs Future 35:409-419. http://dx.doi.org/10.1358/dof.2010.035.05.1484391.
53. Buckner FS, Urbina JA. 2012. Recent developments in sterol 14-demethylase inhibitors for Chagas disease. Int J Parasitol Drugs Drug Resist 2:236-242. http://dx.doi.org/10.1016/j.ijpddr.2011.12.002.